HIGHLIGHTS * Alteryx Inc : Piper Sandler raises to overweight from neutral * Mallinckrodt...* REPORTS EARNINGS FOR THE FIRST QUARTER 2020 AND HIGHLIGHTS PIPELINE PROGRESS* MALLINCKRODT ANNOUNCES POSITIVE FINDINGS IN INOMAX® (NITRIC OXIDE) GAS, FOR INHALATION PHASE 4 OBSERVATIONAL REGISTRY IN NEONATES WITH PULMONARY HYPERTENSION; ENDS TRIAL EARLYMallinckrodt Plc said on Thursday it would fund a trial conducted by medical experts, evaluating the potential benefits of its respiratory therapy, INOmax, as a treatment for lung complications in patients infected with the new coronavirus.Mallinckrodt Plc said on Thursday it would fund a trial conducted by medical experts, evaluating the potential benefits of its respiratory therapy, INOmax, as a treatment for lung complications in patients infected with the new coronavirus. Mallinckrodt is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products. Mallinckrodt Pharmaceuticals has a diverse portfolio of branded products available across a broad range of indications. Mallinckrodt plc. Each product logo below will take you to the product-specific website, where you can learn more about the drug. The Mallinckrodt family had immigrated from Germany. Mallinckrodt Pharmaceuticals is an Irish–tax registered manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents. Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland. Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht.Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. * MALLINCKRODT PLC FILES FOR 4.875% SENIOR NOTES DUE 2020 - SEC FILING Source text for Eikon: [ID:https://bit.ly/2JOH44y] Further company coverage:* MALLINCKRODT INITIATES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR STRATAGRAFT® REGENERATIVE SKIN TISSUE TO U.S. FOOD AND DRUG ADMINISTRATION* MALLINCKRODT PLC SAYS CEO MARK C. TRUDEAU'S FY 2019 TOTAL COMPENSATION WAS $14.6 MILLION VERSUS $14.1 MILLION IN 2018 - SEC FILING* MALLINCKRODT AND NOVOTERIS RECEIVE CLEARANCE FROM HEALTH CANADA TO START PILOT TRIAL OF HIGH-DOSE INHALED NITRIC OXIDE THERAPY FOR COVID-19 INFECTION AND ASSOCIATED LUNG COMPLICATIONS* MALLINCKRODT COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR TERLIPRESSIN FOR THE TREATMENT OF PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 (HRS-1) Source text for Eikon: Further company coverage:Drugmaker Mallinckrodt Plc on Monday warned that a judge's ruling allowing the federal government to force it to pay higher rebates to state Medicaid programs after raising its top-selling drug's price posed an "existential threat to the company. Its segments include Specialty Brands and Specialty Generics.

In 2017 it generated 90% of sales from the U.S. healthcare system.

To learn more about how we use cookies and how you can change your cookies settings, please read our in solving complex challenges, we at Mallinckrodt Pharmaceuticals believe in producing Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company.© 2018 Mallinckrodt. Some aspects of the site may not function properly without cookies enabled.

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Stratatech Biologics License Application (BLA) for StrataGraft®, an investigational regenerative skin tissue therapy in development for the treatment MALLINCKRODT PLC. To learn more about how we use cookies and how you can change your cookies settings, please read our Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company.© 2018 Mallinckrodt. Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland.Mallinckrodt corporate website and will be taken to a The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.